Daré Bioscience, Inc. (NASDAQ:DARE) reported its Q4 2023 earnings, surpassing expectations with a loss of $0.06 per share compared to the expected loss of $0.12 per share. The company focuses on developing pharmaceutical products for women's health and has a diverse portfolio of potential high-impact candidates. In 2023, Daré had 15 interactions with the FDA across six product candidate syndications. They also completed the Phase 2b study for their investigational Sildenafil Cream for female sexual arousal disorder. Daré received IND clearance for DARE-VVA1, a hormone-free candidate for sexual pain, and initiated the Phase 3 study for Ovaprene, their investigational hormone-free monthly contraceptive candidate. Daré has a partnership with Organon for their on-market product XACIATO, indicated for the treatment of bacterial vaginosis, which could result in double-digit royalties and up to $180 million in milestone payments. They also have a commercialization agreement with Bayer for Ovaprene, which has the potential to generate up to $310 million in commercial milestones and double-digit-tiered royalties. Daré reported a net loss of $30.1 million for 2023 and ended the year with approximately $10.5 million in cash and cash equivalents. The company is exploring various financing opportunities to support its operations and advance its product candidates [b82c3dde].